GlassScriptPhysician profile
Cindy O Scharfen
NPI 1861582322
$5,122.13
in general payments reported to CMS, 2019-2025
47 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $421 · 2021: $1,141 · 2022: $1,000 · 2023: $126 · 2024: $478 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $499.84 | 2019-2025 | Tagrisso, Imfinzi, Lynparza |
| Glaxosmithkline, LLC. | $436.61 | 2021-2025 | Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $342.47 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pharmacyclics LLC, An Abbvie Company | $286.26 | 2021-2022 | |
| Eisai INC. | $261.54 | 2019-2022 | |
| Lilly USA, LLC | $257.45 | 2019-2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $211.88 | 2019-2025 | |
| Janssen Biotech, INC. | $210.30 | 2019-2025 | Carvykti, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $209.58 | 2019-2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $208.25 | 2022-2025 | Libtayo |
| Amgen INC. | $190.06 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $160.93 | 2019-2025 | |
| Daiichi Sankyo INC. | $157.05 | 2020-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $150.44 | 2019-2023 | Ultomiris |
| Genzyme Corporation | $144.92 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Scharfen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.